Cargando…
A novel small molecule agent displays potent anti-myeloma activity by inhibiting the JAK2-STAT3 signaling pathway
The oncogenic STAT3 signaling pathway is emerging as a promising target for the treatment of multiple myeloma (MM). In the present study, we identified a novel STAT3 inhibitor SC99 in a target-based high throughput screen. SC99 inhibited JAK2-STAT3 activation but had no effects on other transcriptio...
Autores principales: | Zhang, Zubin, Mao, Hongwu, Du, Xiaolin, Zhu, Jingyu, Xu, Yujia, Wang, Siyu, Xu, Xin, Ji, Peng, Yu, Yang, Cao, Biyin, Han, Kunkun, Hou, Tingjun, Xu, Zhuan, Kong, Yan, Jiang, Gaofeng, Tang, Xiaowen, Qiao, Chunhua, Mao, Xinliang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891041/ https://www.ncbi.nlm.nih.gov/pubmed/26814430 http://dx.doi.org/10.18632/oncotarget.6974 |
Ejemplares similares
-
Correction: A novel small molecule agent displays potent anti-myeloma activity by inhibiting the JAK2-STAT3 signaling pathway
por: Zhang, Zubin, et al.
Publicado: (2016) -
An inhibitor of cholesterol absorption displays anti-myeloma activity by targeting the JAK2-STAT3 signaling pathway
por: Xu, Xin, et al.
Publicado: (2016) -
A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma
por: Zhu, Jingyu, et al.
Publicado: (2014) -
Correction: A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma
por: Zhu, Jingyu, et al.
Publicado: (2019) -
SC06, a novel small molecule compound, displays preclinical activity against multiple myeloma by disrupting the mTOR signaling pathway
por: Han, Kunkun, et al.
Publicado: (2015)